Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-07275315 dose 1, Tilrekimig
PF-07275315 · 3 trials · 3 indications
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Exacerbation of Chronic Obstructive Pulmonary Disease (ECOPD) are sudden worsening of respiratory symptoms that significantly worsen lung function and quality of life.
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Incidence of treatment-emergent AEs, treatment-emergent SAEs, and treatment-emergent AEs/SAEs leading to treatment discontinuation
Incidence of clinically significant changes in laboratory tests
Incidence of clinically significant changes in vital signs
Incidence of clinically significant changes in ECG
EASI75 (≥75% improvement from baseline) at Week 16
| Arm | Type | Description |
|---|---|---|
| Phase 3 Treatment Arm A | EXPERIMENTAL | - |
| Phase 2 Treatment Arm B | EXPERIMENTAL | - |
| Phase 2 Treatment Arm A | EXPERIMENTAL | - |
| Phase 3 Treatment Arm B | PLACEBO_COMPARATOR | - |
| Phase 2 Treatment Arm C | PLACEBO_COMPARATOR | - |
| Treatment Arm A | EXPERIMENTAL | PF-07275315 |
| Treatment Arm B | EXPERIMENTAL | PF-07275315 |
| Treatment Arm C | EXPERIMENTAL | PF-07275315 |
| Treatment Arm D | PLACEBO_COMPARATOR | Placebo |
| Stage 1_PF-07275315 | EXPERIMENTAL | Stage 1 PF-07275315 Injections over 12 weeks |
| Stage 1_PF-07264660 | EXPERIMENTAL | Stage 1 PF-07264660 Injections over 12 weeks |
| Stage 1_Placebo | EXPERIMENTAL | Stage 1 Placebo Injections over 12 weeks |
| Stage 2_PF-07275315 _Dose A | EXPERIMENTAL | Stage 2 PF-07275315 Injections over 12 weeks. |
| Stage 2_PF-07275315 _Dose B | EXPERIMENTAL | Stage 2 PF-07275315 Injections over 12 weeks. |
| Stage 2_PF-07275315 _Dose C | EXPERIMENTAL | Stage 2 PF-07275315 Injections over 12 weeks. |
| Stage 2_PF-07275315 _Dose D | EXPERIMENTAL | Stage 2 PF-07275315 or PF-07264660 Injections over 12 weeks. |
| Stage 2_Placebo | EXPERIMENTAL | Stage 2 Placebo Injections over 12 weeks. |
| Stage 3_Placebo+PF-07275315_Dose A | EXPERIMENTAL | Stage 3 Placebo Injections for 16 weeks followed by PF-07275315 Injections for 16 weeks. |
| Stage 3_PF-07275315_Dose B | EXPERIMENTAL | Stage 3 PF-07275315 Injections for 32 weeks. |
| Stage 4_PF-07264660_Dose A | EXPERIMENTAL | Stage 4 PF-07264660 Injections for 12 weeks |
| Stage 4_PF-07264660_Dose B | EXPERIMENTAL | Stage 4 PF-07264660 Injections for 12 weeks |
| Stage 4_PF-07264660_Dose C | EXPERIMENTAL | Stage 4 PF-07264660 Injections for 12 weeks |
| Stage 4_Placebo | EXPERIMENTAL | Stage 2 Placebo Injections for 12 weeks |
| Name | Type | Description |
|---|---|---|
| PF-07275315 dose 1 | DRUG | SC injection dose 1 |
| PF-07275315-dose 2 | DRUG | SC injection dose 2 |
| Placebo | DRUG | SC injection matched |
| PF-07275315-dose 3 | DRUG | SC injection dose 3 |
| PF-07275315 | DRUG | subcutaneous injection |
| PF-07264660 | DRUG | subcutaneous injection |
Key Inclusion Criteria: * Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition). * Spirometry values (post-bronchodilator forced expiratory volume in 1 second \[FEV1\]/forced vital capac...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PF-07275315 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for respiratory and inflammatory conditions. It is being studied in Phase 2 clinical trials for moderate to severe chronic obstructive pulmonary disease, moderate to severe asthma, and atopic dermatitis. It is not described as approved and remains in clinical development.
PF-07275315 targets the cytokines IL-4, IL-13, and TSLP. These cytokine targets place it in the cytokine target class, and the drug is formulated as a small molecule. Its clinical program spans respiratory and inflammatory indications, including asthma, atopic dermatitis, and moderate to severe COPD.
PF-07275315 is being studied for moderate to severe chronic obstructive pulmonary disease, moderate to severe asthma, and atopic dermatitis. These are investigational uses in Phase 2 trials, not approved indications. The COPD and asthma studies are recruiting, while the atopic dermatitis study is active but no longer recruiting.
Pfizer, Inc. (ticker PFE) develops PF-07275315. Pfizer is running the Phase 2 program across three indications: moderate to severe COPD, moderate to severe asthma, and atopic dermatitis. The trials enroll adults, with the COPD study starting at age 35 and the asthma and atopic dermatitis studies starting at age 18.
PF-07275315 is in Phase 2 clinical development. All three of its listed studies are Phase 2 trials. The COPD and asthma studies are currently recruiting, and the atopic dermatitis study is active but not recruiting. The program has not been described as FDA approved and remains investigational.
PF-07275315 is in three Phase 2 trials: NCT07363694 in moderate to severe COPD, NCT06977581 in moderate to severe asthma, and NCT05995964 in moderate to severe atopic dermatitis. All are randomized, double-blind, and placebo-controlled. The COPD trial is the largest, with planned enrollment of 1,156 participants across 18 countries.
PF-07275315 dose 1 refers to a dose level of PF-07275315, the investigational small molecule from Pfizer (ticker PFE). Searches for PF-07275315 dose 1 point to the same drug candidate being studied in Phase 2 trials for moderate to severe COPD, moderate to severe asthma, and atopic dermatitis.